Objective To describe the normative serum cortisol levels during 25 to 29 weeks of POG and the association of maternal, psychological, and social factors on serum cortisol in the second and third trimesters in a cohort of pregnant women.

Methods All eligible pregnant women registered in the maternal care program in Anuradhapura district, Sri Lanka from July to September 2019 were invited to the Rajarata Pregnancy Cohort (RaPCo). An interviewer-administered questionnaire-based symptom analysis and clinical assessment were conducted at baseline in the first trimester and at follow-up from 25 to 29 weeks POG. We assessed fasting early morning serum cortisol levels at the follow-up visit.

Results The study sample included 1010 pregnant women with a mean age in years and POG in weeks at baseline of 28 (±6) and 10 (±3), respectively. The mean (SD, 97% percentile) serum cortisol level in all pregnant women was 10.93 (±3.83, 20.95) μg/dL, with no significant difference between singleton and twin pregnancies (p=0.138). None of the study participants had a cortisol level exceeding the upper limit of 42 μg/dL, and 464 (45.9%) had levels less than 10 μg/dL. Serum cortisol levels were higher in women with an advanced POG with a mean of 10.33 µg/dL (95%CI: 9.68–10.98) at 24 weeks POG and 12.23 µg/dL (95%CI: 11.15–13.32) at 29 weeks POG (p=0.049). Primi-gravidity (p=0.004), history of miscarriage (p=0.010), BMI categories (p=0.044), and POG (p=0.002) were independently associated with serum cortisol levels in robust regression. An EPDS score of more than 9 was not associated with serum cortisol (p=0.633).

Conclusion The pregnant women in rural Sri Lanka reported a low mean serum cortisol level, which gradually increased with the POG. Significantly higher mean serum cortisol was associated with primi-gravidity, history of miscarriage, pre-pregnancy BMI, and POG at cortisol test but not psychological factors.

The authors have declared no competing interest.

Yes

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical approval for the study was obtained from the Ethics Review Committee of the FMAS, RUSL (ERC/2019/). Informed written consent was obtained from the participant, and if the participant was less than 18 years of age, consent from parent(s) and/or guardian(s) and written assent from the participant was obtained before recruiting to the study.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All deidentified data of the participants included in the current study of the Rajarata Pregnancy Cohort (RaPCO) is deposited under the doi 10.5281/zenodo.15074568 at the https://zenodo.org/records/15074568.